Medical Research News

Cannabinoids for Epilepsy: CBDv

Written by Cara Wietstock

Cannabidivarin (CBDv) is a valuable resource as one of the anticonvulsant cannabinoids.

With the synergistic effects and creation of cannabinoids, it is sometimes hard to note the difference between certain compounds. It has been noted that feral populations of Cannabis Indica have shown to test high in CBDv. Landrace strains from northwest India and hashish from Nepal have also had notoriously high CBDv levels. Like CBD, CBDv has seven double bond isomers and 30 stereoisomers. It is a homolog of CBD with the side-chain shortened by two methylene bridges.

Currently, CBDv is not scheduled by the Convention of Psychotropic Substances. GW Pharmaceuticals is actually developing CBDv due to previously observed anticonvulsive and antiepileptic action. The cannabinoid has now been studied as an anticonvulsant in adults and children by GW Pharm.


CBDv is a cannabinoid that can be used for more than just a treatment for epilepsy. It can also be used as a mood stabilizer and treatment for symptoms of chronic pain and inflammation. GW Pharmaceuticals has also begun Phase 1 clinical trials for CBDv to treat Autism spectrum disorders.

Strains that are more likely to contain CBDv are Critical Mass, Harlequin, Mandarin Kush, Island Sweet Skunk, Boston OG, and Shark Shock. Though these strains should have a higher concentration of CBDv, the best way to administer this medicine is using an extraction. This is specifically ideal when dosing children, it is good to know the levels of THC are as low as possible before administering medical cannabis to children.  


This cannabinoid is definitely lesser known than the heavy hitters. That is probably because CBD gets most of the attention as the parent cannabinoid. Whatever the reason, CBDv is worth talking about since whole plant medicine is the most ideal with cannabis flowers and leaves.


Chemical Formula: C19H26O2
Molecular Weight: 286.41

About the author

Cara Wietstock

Cara began working in the retail cannabis industry of San Francisco, CA in 2011 and continued in that sector for years. In 2015 she dedicated herself to writing full-time. Her passion for the written word and deep respect for the healing properties of the plant have brought her to Terpenes and Testing magazine. She now helps keep us on the cutting edge of scientific cannabis discovery as the Editor-in-Chief of the print publication.

Leave a Comment